Accuray Incorporated (ARAY) CFO Sells $36,199.24 in Stock
Accuray Incorporated (NASDAQ:ARAY) CFO Kevin Waters sold 7,154 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $5.06, for a total value of $36,199.24. Following the completion of the transaction, the chief financial officer now owns 335,087 shares of the company’s stock, valued at approximately $1,695,540.22. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Accuray Incorporated (ARAY) traded up $0.10 during mid-day trading on Friday, hitting $5.25. The company had a trading volume of 1,641,858 shares, compared to its average volume of 713,905. The company has a current ratio of 1.48, a quick ratio of 0.92 and a debt-to-equity ratio of 2.44. Accuray Incorporated has a twelve month low of $3.60 and a twelve month high of $6.00.
Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. The business had revenue of $91.00 million for the quarter, compared to analyst estimates of $88.26 million. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.12) EPS. sell-side analysts expect that Accuray Incorporated will post -0.18 earnings per share for the current year.
A number of research firms have weighed in on ARAY. Lake Street Capital began coverage on Accuray in a report on Thursday. They issued a “buy” rating and a $10.00 price target for the company. BTIG Research restated a “hold” rating on shares of Accuray in a report on Thursday, August 24th. Cowen restated a “buy” rating and issued a $9.00 price target on shares of Accuray in a report on Friday, October 27th. Zacks Investment Research cut Accuray from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Finally, Jefferies Group cut their target price on Accuray from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, August 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $6.82.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/01/accuray-incorporated-aray-cfo-sells-36199-24-in-stock.html.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.